eligibility_summary
Eligibility: Untreated PMBCL, age 18-75, life expectancy >=6 mo, IPI 0-3, ECOG 0-2, clinician deems suitable, labs: WBC >=3, ANC >=1.5, PLT >=100 (x10^9/L), creatinine <=1.5 mg/dL or CrCl >=50 mL/min, ALT/AST <=3x ULN, bilirubin <=2x ULN, consent, no other anti-PMBCL drugs. Exclude: other cancer <5 yrs, other trials or prior lymphoma therapy, allergy, prior allogeneic transplant, pregnant/lactating, serious infections (HIV, active HBV/HCV), investigator-judged risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm, multicenter first-line study in untreated primary mediastinal large B-cell lymphoma (PMBCL) testing: 1) Sintilimab: anti–PD-1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-1 to restore and enhance T‑cell antitumor activity. 2) R-CHOP components: Rituximab (anti‑CD20 monoclonal antibody) depleting malignant B cells via ADCC/CDC/apoptosis, Cyclophosphamide (alkylating agent) causing DNA crosslinking, Doxorubicin or liposomal doxorubicin (anthracycline, topoisomerase II inhibitor, DNA intercalator, ROS generation), Vincristine (vinca alkaloid, microtubule inhibitor) causing mitotic arrest, Prednisone (glucocorticoid) inducing lymphocyte apoptosis. Targets/pathways: PD-1/PD-L1 axis on T cells, CD20 on B cells, DNA replication/repair (alkylation), topoisomerase II, microtubule dynamics, and glucocorticoid receptor–mediated apoptosis.